← Eichor
Study identifier: NCT07096128 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

Condition: mCRPC  ·  Sponsor: Jinming Zhang

PhasePhase 1
Planned participants36
Who can joinMale, 18 Years to no upper limit
Healthy volunteersNo

About this study

This was a multicenter, open-label, phase I study to evaluate the safety, tolerability, radiation dosimetry and efficacy of \[177Lu\] Lu-PSMA-XT injection in patients with metastatic prostate cancer .

This description comes directly from the study's public registry record.

Talk to the study team

Jinming Zhang  ·  (+86)010-66936108  ·  Zhangjm301@163.com

Jinming Zhang  ·  +861066936108  ·  Zhangjm301@163.com

Always discuss trial participation with your own doctor first.

Locations (3)

Beijing Cancer HospitalBeijing, Beijing Municipality, ChinaRecruiting
Mianyang Central HospitalBeijing, Beijing Municipality, ChinaRecruiting
The First Medical Center, Chinese PLA General HospitalBeijing, Beijing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07096128